التفاصيل البيبلوغرافية
| العنوان: |
DataSheet_1_The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses.docx |
| المؤلفون: |
Lu Zhang, Hongquan Chen, Su Yang, Yang Zhao, Xiaoyun Shen, Xiaowen He, Haohui Ye, Deqin Wang, Jiazhou Lou, Yinshan Wang, Shengjun Wu |
| سنة النشر: |
2022 |
| المجموعة: |
Frontiers: Figshare |
| مصطلحات موضوعية: |
Immunology, Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies), Autoimmunity, Cellular Immunology, Humoural Immunology and Immunochemistry, Immunogenetics (incl. Genetic Immunology), Innate Immunity, Transplantation Immunology, Tumour Immunology, Immunology not elsewhere classified, Genetic Immunology, Animal Immunology, Veterinary Immunology, SARS-CoV-2, booster vaccination, neutralization breadth, variants, Omicron |
| الوصف: |
Although immune response enhancement has been reported after primary and booster vaccines of CoronaVac, neutralization breadth of SARS-CoV-2 variants is still unclear. In the present study, we examined the neutralization magnitude and breadth of SARS-CoV-2 variants including Beta (B.1.351), Delta (B.1.617.2) and Omicron (B.1.1.529) in 33 convalescent COVID-19 patients and a cohort of 55 medical staff receiving primary CoronaVac vaccines and an additional homologous booster dose. Results showed that, as compared with the two-dose primary vaccination, the homologous booster dose achieved 2.24-, 3.98-, 4.58- and 2.90-fold increase in neutralization titer against wild-type, Beta, Delta, and Omicron, respectively. After booster dose, neutralization titer reduction for variants was less than that after the primary vaccine or that for convalescents. The proportion of recipients able to neutralize 2 or more variants increased from 36.36% post the primary vaccination to 87.27% after the booster. Significant increase in neutralization breadth of 1.24 (95% confidence interval (CI), 0.89–1.59) variants was associated with a log 10 increase in neutralization titer against the wild-type. In addition, anti-RBD IgG level was identified as an excellent surrogate for positive neutralization of SARS-CoV-2 and neutralization breadth of variants. These findings highlight the value of an additional homologous CoronaVac dose in broadening the cross-neutralization against SARS-CoV-2 variants, and are critical for informing the booster dose vaccination efforts. |
| نوع الوثيقة: |
dataset |
| اللغة: |
unknown |
| العلاقة: |
https://figshare.com/articles/dataset/DataSheet_1_The_impact_of_CoronaVac_on_the_neutralization_breadth_and_magnitude_of_the_antibody_response_to_SARS-CoV-2_viruses_docx/21160531Test |
| DOI: |
10.3389/fimmu.2022.990071.s001 |
| الإتاحة: |
https://doi.org/10.3389/fimmu.2022.990071.s001Test
https://figshare.com/articles/dataset/DataSheet_1_The_impact_of_CoronaVac_on_the_neutralization_breadth_and_magnitude_of_the_antibody_response_to_SARS-CoV-2_viruses_docx/21160531Test |
| حقوق: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.C0BF9678 |
| قاعدة البيانات: |
BASE |
